|
10:50 - 11:00 |
[B006] Collagen family proteins, thrombospondin 1 and lumican are differentially expressed across breast cancer subtypes by functional proteomics: a preliminary study with bioinformatics analysis |
Chi-Cheng Huang
|
|
|
|
|
11:00 - 11:10 |
[B003] Integrative Omics Analysis Reveals DTX1 as a Key Marker and Drug Target in Breast Cancer |
Yen-Dun Tzeng
|
|
|
|
|
11:10 - 11:20 |
[B009] Therapeutic Co-Targeting of the BTK/HER2 Axis Induces Iron Accumulation to Overcome Trastuzumab Resistance in HER2-Positive Breast Cancer |
Chih-Ming Su
|
|
|
|
|
11:20 - 11:30 |
[B004] ATP synthasome contributes to efficient energy flux in malignant breast cancer |
Chia-Jung Li
|
|
|
|
|
11:30 - 11:40 |
[B016] The application of a PI3K inhibitor and an AKT inhibitor in HER2-positive breast cancer cells with resistance to HER2-directed antibody-drug conjugates |
Wei-Pang Chung
|
|
|
|
|
11:40 - 11:50 |
[B013] Targeting the USP7-CDK1 axis suppresses estrogen receptor-positive breast cancer progression |
Joseph Lin
|
|
|
|
|
11:50 - 12:00 |
[B015] SLC6A14-Mediated Glutamine Metabolism Reprogramming Enhances Cancer Stemness for Early Onset of Breast Cancer |
Meng-Xia Su
|
|
|
|
|
12:00 - 12:10 |
[B001] Discovery and Biological Evaluation of a Novel Inhibitor for Human Breast Cancer Treatment |
Cheng-Chiao Huang
|
|
|
|
|
12:10 - 12:20 |
[C025] Enhancing the Detection of Contralateral Breast Cancer in Breast Cancer Survivors Using Artificial Intelligence |
Jijung Jung
|
|
|
|
|
12:20 - 12:30 |
[C013] Pattern of failure and timing of progression on CDK4/6 inhibitor as first line therapy for HR+HER2- metastatic breast cancer invading different organ |
Ruoh-Yun Kao
|
|
|
|
|
13:10 - 13:20 |
[B010] Prognostic effects of ABCB1 and TMEM14B expression in triple-negative breast cancer |
Sin-Hua Moi
|
|
|
|
|
13:20 - 13:30 |
[B025] Co-targeting PD-L1 and CDK4 benefits plasticizer-associated early-onset breast cancer |
Shu-Wei Hu
|
|
|
|
|
13:30 - 13:40 |
[B024] Mechanistic Insights into Melittin’s Efficacy Against Tamoxifen-Resistant Breast Cancer: Apoptosis, Proliferation, and Migration Modulation |
Min-Hua Wu
|
|
|
|
|
13:40 - 13:50 |
[B005] LOC100506691, a long noncoding RNA, acts as novel oncogene in regulating breast cancer growth |
Kian-Hwee Chong
|
|
|
|
|
13:50 - 14:00 |
[B014] Molecular characterization of HER2 low breast cancers reveals a biologically and clinically distinct entity with heterozygous loss of ERBB2 |
Xintao Qiu
|
|
|
|
|
14:00 - 14:10 |
[C016] Using Bilateral Thoracoabdominal Flaps for Extensive Defects After Bilateral Mastectomy for Inflammatory Breast Cancer |
Ryohei Katsuragi
|
|
|
|
|
14:10 - 14:20 |
[C061] Case Report of Stereotactic Body Radiation Therapy for Oligometastatic Breast Cancer Patient |
Masahiro Yoshida
|
|
|
|
|
14:20 - 14:30 |
[B023] exoLinc-p21s: a short lincRNA-p21-engineered exosome as a chemosensitizer for targeting DDB2-mediated DNA repair |
Yu-Hao He
|
|
|
|
|
14:30 - 14:40 |
[C009] LXPB5268 combined with neoadjuvant chemotherapy in early-stage Triple-Negative Breast Cancer patients |
Chin-Yin Kuo
|
|
|
|
|
15:00 - 15:10 |
[C037] Multi-omics and spatial transcriptomics unveil the role of ferroptosis suppressor FANCD2 in clinicopathology and predicting immunotherapy response in breast cancer |
Hung-Yu Lin
|
|
|
|
|
15:10 - 15:20 |
[C074] Combination of endocrine therapy, gonadotropin-releasing hormone agonist, and immunotherapy enhance immune activation in premenopausal ER+/HER2- metastatic breast cancer patients: final updates from PEER study |
I-Chun Chen
|
|
|
|
|
15:20 - 15:30 |
[C030] Circulating CD3+CD8+ T lymphocytes as indicators of disease status in patients with early breast cancer |
Hui-Ping Hsu
|
|
|
|